EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 3.0

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects

Xu Jiang iD, Sungyeun Bae iD, Deok Yong Yoon, Shin Jung Park, Jaeseong Oh iD, Joo-Youn Cho iD, Kyung-Sang Yu iD

Drug Design, Development and Therapy · 2023

DOI: 10.2147/dddt.s409368 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2023. Verfasst von Xu Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicAdultHumansHealthy VolunteersCross-Over StudiesArea Under CurveTherapeutic EquivalencyAdministration, OralRepublic of KoreaTabletsBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

CKD-370L-prolineT2DMbiosimilarcocrystal

Substanzen

TabletsempagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
  • Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA.
  • Department of Pharmaceutical Research Laboratory, Chong Kun Dang Research Institute, Chong Kun Dang Pharmaceutical Corporation, Yongin, Republic of Korea.
  • Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Xu Jiang, Sungyeun Bae, Jaeseong Oh, Joo-Youn Cho, Kyung-Sang Yu

Zitieren

APA

Jiang, X., Bae, S., Yoon, D. Y., Park, S. J., Oh, J., Cho, J. Y., & Yu, K. S. (2023). Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s409368

Vancouver

Jiang X, Bae S, Yoon DY, Park SJ, Oh J, Cho JY, et al. Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects. Drug Design, Development and Therapy. 2023. doi:10.2147/dddt.s409368

BibTeX
@article{Jiang2023,
  author = {Jiang, Xu and Bae, Sungyeun and Yoon, Deok Yong and Park, Shin Jung and Oh, Jaeseong and Cho, Joo-Youn and Yu, Kyung-Sang},
  title = {Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects},
  journal = {Drug Design, Development and Therapy},
  year = {2023},
  doi = {10.2147/dddt.s409368}
}
Kostenlos starten →